- Home
- QLGN vs THAR Comparison
QLGN vs THAR Comparison
Compare QLGN & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- THAR
- Stock Information
- Founded
- QLGN 1996
- THAR 2017
- Country
- QLGN United States
- THAR United States
- Employees
- QLGN N/A
- THAR N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- THAR Health Care
- Exchange
- QLGN Nasdaq
- THAR Nasdaq
- Market Cap
- QLGN 2.2M
- THAR 2.4M
- IPO Year
- QLGN N/A
- THAR 2022
- Fundamental
- Price
- QLGN $3.48
- THAR $1.20
- Analyst Decision
- QLGN
- THAR Strong Buy
- Analyst Count
- QLGN 0
- THAR 1
- Target Price
- QLGN N/A
- THAR $17.00
- AVG Volume (30 Days)
- QLGN 158.4K
- THAR 97.3K
- Earning Date
- QLGN 05-06-2025
- THAR 05-08-2025
- Dividend Yield
- QLGN N/A
- THAR N/A
- EPS Growth
- QLGN N/A
- THAR N/A
- EPS
- QLGN N/A
- THAR N/A
- Revenue
- QLGN N/A
- THAR N/A
- Revenue This Year
- QLGN N/A
- THAR N/A
- Revenue Next Year
- QLGN N/A
- THAR N/A
- P/E Ratio
- QLGN N/A
- THAR N/A
- Revenue Growth
- QLGN N/A
- THAR N/A
- 52 Week Low
- QLGN $2.85
- THAR $0.95
- 52 Week High
- QLGN $29.45
- THAR $6.45
- Technical
- Relative Strength Index (RSI)
- QLGN 52.85
- THAR 43.85
- Support Level
- QLGN $3.10
- THAR $1.05
- Resistance Level
- QLGN $4.40
- THAR $1.28
- Average True Range (ATR)
- QLGN 0.40
- THAR 0.11
- MACD
- QLGN 0.05
- THAR 0.02
- Stochastic Oscillator
- QLGN 40.32
- THAR 75.58
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.